ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Bristol-Myers Nominations Open

August 10, 1979

Margaret Kripke Comes Out of Retirement To Become Chief Scientific Officer at CPRIT

December 14, 2012

ASCO, AACR Call NCI Bypass Budget A Key Advocacy Tool, Seek Larger Role In Writing It.

July 14, 2000

Zerhouni Appoints Kington As Deputy Director

February 14, 2003

Tamoxifen Trial Enrolls 19% Of Women Needed, Fisher Reports To NCAB

October 16, 1992

NCI Contract Process Requires Eight Months, Probably Will Get Longer As Program Grows

February 8, 1974